Project Grant DP2AI200969
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $430K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Knoxville, TN 37996, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $148,519 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop adipose-derived stem cells as an in vitro model system for human cytomegalovirus latency. The recipient will establish conditions under which adipose-derived stem cells support latent HCMV infection and characterize the transcriptional program of latency using RNA sequencing, comparing...
- The National Institute of Allergy and Infectious Diseases awarded University of Tennessee Health Science Center $468,368 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate LGR4 expression and its role in HIV-associated atherosclerosis. The research examines molecular mechanisms linking controlled HIV infection to macrophage activation and accelerated atherosclerosis in people living with HIV on antiretroviral therapy. Using an experimental...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $235,550 on July 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI196150). The award funds research into systemic and phagosomal heat as regulators of neutrophil immunity during bacterial infection. The project investigates how febrile temperatures reprogram neutrophil metabolism and function to enhance antibacterial defense against...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $127,932 on March 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate neuraminidase as a target antigen for a universal influenza virus vaccine. The research addresses the gap between current seasonal influenza vaccines, which elicit only strain-specific immunity with variable effectiveness and provide no protection against novel pandemic...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $163,852 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the septation initiation network (SIN) kinase cascade in Aspergillus fumigatus, with the goal of enhancing echinocandin antifungal efficacy against invasive pulmonary aspergillosis. The research interrogates SIDB-dependent septation mechanisms that confer...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $414,305 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate influenza neuraminidase structure and dynamics with emphasis on how stalk variation impacts enzymatic function and immune recognition. The research addresses structural variation in influenza neuraminidase, a sialidase that cleaves sialic acid from host glycoproteins and glycolipids,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...
- The National Institute of Allergy and Infectious Diseases awarded East Tennessee State University $142,785 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize neutrophil swarming responses to fungal pathogens relevant to diabetes mellitus. The research addresses invasive fungal infections caused by Candida, Aspergillus, and Zygomycetes species that pose serious public health threats in immunocompromised patients, including those with...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $678,934 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel host-adaptation mechanisms regulating Aspergillus fumigatus pathogenic fitness in invasive aspergillosis. The recipient will conduct basic science research identifying and characterizing new antifungal targets for invasive mold infection caused by A. fumigatus,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $200,233 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a cross-protective vaccine against leptospira infection. The award funds research to identify and evaluate conserved antigenic epitopes from leptospira species using reverse and structural vaccinology approaches combined with high-throughput microarray screening. The recipient will confirm...